Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:CRDL NASDAQ:ENGN NASDAQ:LIXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$0.98-0.1%$1.16$0.94▼$1.89$30.50M-0.06150,642 shs25,301 shsCRDLCardiol Therapeutics$1.05-1.4%$1.23$0.88▼$1.71$120.44M0.72515,671 shs142,139 shsENGNenGene$1.78+2.6%$3.05$1.40▼$12.25$118.91M-0.31.07 million shs238,500 shsLIXTLixte Biotechnology$7.99+7.7%$5.81$1.28▼$8.25$117.82M1.27132,041 shs65,082 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-1.01%-3.92%-22.22%-1.01%-30.00%CRDLCardiol Therapeutics+2.91%+0.95%-13.11%-24.29%-22.06%ENGNenGene-2.81%+1.17%-6.49%-74.41%-52.47%LIXTLixte Biotechnology-7.71%+1.64%+18.72%+141.69%+719.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$0.98-0.1%$1.16$0.94▼$1.89$30.50M-0.06150,642 shs25,301 shsCRDLCardiol Therapeutics$1.05-1.4%$1.23$0.88▼$1.71$120.44M0.72515,671 shs142,139 shsENGNenGene$1.78+2.6%$3.05$1.40▼$12.25$118.91M-0.31.07 million shs238,500 shsLIXTLixte Biotechnology$7.99+7.7%$5.81$1.28▼$8.25$117.82M1.27132,041 shs65,082 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-1.01%-3.92%-22.22%-1.01%-30.00%CRDLCardiol Therapeutics+2.91%+0.95%-13.11%-24.29%-22.06%ENGNenGene-2.81%+1.17%-6.49%-74.41%-52.47%LIXTLixte Biotechnology-7.71%+1.64%+18.72%+141.69%+719.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$5.00410.73% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50713.40% UpsideENGNenGene 2.14Hold$11.05522.28% UpsideLIXTLixte Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ATNM, LIXT, ENGN, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CRDLCardiol Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026ENGNenGene Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeEqual Weight ➝ Underweight$3.006/16/2026ENGNenGene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $4.005/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.005/8/2026ENGNenGene CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Outperform ➝ Market Perform5/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$25.00 ➝ $2.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$90K341.29N/AN/A$1.31 per share0.75CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AENGNenGeneN/AN/AN/AN/A$3.81 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$0.75N/AN/AN/AN/A-100.85%-47.89%N/ACRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)ENGNenGene-$117.30M-$2.17N/AN/AN/AN/A-56.06%-45.64%9/14/2026 (Estimated)LIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/ALatest ATNM, LIXT, ENGN, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q2 2026ENGNenGene-$0.48$0.43+$0.91$0.43N/AN/A5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25CRDLCardiol TherapeuticsN/A4.394.39ENGNenGene0.1012.5712.57LIXTLixte BiotechnologyN/A2.782.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%CRDLCardiol Therapeutics12.49%ENGNenGene64.16%LIXTLixte Biotechnology5.10%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals0.60%CRDLCardiol Therapeutics5.25%ENGNenGene10.50%LIXTLixte Biotechnology9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.38 million29.32 millionOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableENGNenGene3166.99 million59.95 millionN/ALIXTLixte Biotechnology415.02 million13.59 millionNot OptionableATNM, LIXT, ENGN, and CRDL HeadlinesRecent News About These CompaniesLIXTE joins Russell Microcap IndexJune 26, 2026 | msn.comLIXTE Joins Russell Microcap IndexJune 26, 2026 | globenewswire.comLIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026June 18, 2026 | globenewswire.comLixte Biotechnology Pivoting to Nomad Power Solutions MergerJune 16, 2026 | tipranks.comThe New Bottleneck Isn’t Computing Power — It’s Just PowerJune 12, 2026 | markets.businessinsider.comFrom Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power CrunchJune 12, 2026 | newswire.caLixte Biotechnology Shares Down on Plans for Nomad Transportable Power Deal, Name ChangeJune 12, 2026 | marketwatch.comLIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)June 12, 2026 | globenewswire.comLixte Biotechnology Announces At-the-Market Equity FinancingJune 4, 2026 | tipranks.comLIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic GrowthJune 3, 2026 | globenewswire.comLIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of DirectorsJune 1, 2026 | globenewswire.comLIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress UpdateMay 14, 2026 | globenewswire.comLIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer TreatmentApril 28, 2026 | finance.yahoo.comLIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer TreatmentApril 27, 2026 | financial-news.co.ukLIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment LandscapeApril 21, 2026 | financial-news.co.ukLixte Biotechnology Updates Executive Equity Compensation With RSUsApril 17, 2026 | tipranks.comLIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO ConferenceApril 13, 2026 | usatoday.comFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care ConferenceApril 13, 2026 | globenewswire.comLixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic PartnershipsApril 10, 2026 | financial-news.co.ukLixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic PartnershipsApril 10, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNM, LIXT, ENGN, and CRDL Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$0.98 0.00 (-0.10%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Cardiol Therapeutics NASDAQ:CRDL$1.04 -0.02 (-1.42%) As of 12:29 PM Eastern This is a fair market value price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.enGene NASDAQ:ENGN$1.78 +0.05 (+2.60%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Lixte Biotechnology NASDAQ:LIXT$7.99 +0.57 (+7.65%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Comcast’s NBCUniversal Split Puts Broadband Back in Focus Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push 3 European Stocks to Carry Investors Through the Back Half of 2026 3 Charts That Could Change the Course of Summer Trading Short Squeeze Alert—Moderna Stock Surges on New Strategy 3 ETFs Offering Exposure to Latin America’s Stock Market Rally These 3 Dividend Stocks Could Boost Your Income This July Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
